Login to Your Account

Cardiome, P&G, Others Jostle

Growing AF Market Players Still In Line: Who Will Lead?

By Randall Osborne

Monday, August 27, 2007
Cardiome Pharma Corp.'s strong Phase III data in June with intravenous vernakalant for atrial fibrillation (AF) or atrial flutter after coronary artery bypass graft (CABG) surgery may have opened the door for off-label use in new-onset AF, and also may have cleared a somewhat smoother regulatory path for the product. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription